Asymchem is a leading global contract research organization (CRO) providing integrated pharmaceutical solutions and services. Founded in 1998, the company is headquartered in Morrisville, North Carolina, United States. Primarily focused on drug development and manufacturing, Asymchem offers a wide range of products and services.

These include custom synthesis, generic active pharmaceutical ingredient (API), intermediates, and drug product manufacturing, analytical services, process development, and regulatory support. The company serves both pharmaceutical and biotechnology companies, globally. On a global scale, Asymchem has a strong presence with subsidiaries and joint ventures in various countries.

The company has subsidiaries in China, Europe, and Japan, as well as strategic partnerships in Asia and North America. This global network allows Asymchem to offer its services to clients across different regions effectively. In terms of market position, Asymchem is considered one of the leading global CROs in the pharmaceutical industry.

The company has achieved substantial growth, with a significant market share and has established a strong reputation for its high-quality products and services. Asymchem competes with other major CROs such as Lonza Group, GenScript, and WuXi AppTec. Over the years, Asymchem has experienced many significant events and achievements.

In 2009, the company expanded its manufacturing capacity by opening a state-of-the-art facility in Tianjin, China. In 2011, Asymchem acquired CMC Biologics Laboratories, strengthening its capabilities in biopharmaceutical development and manufacturing. These strategic moves have contributed to the company's growth and success.

As of the latest updates, Asymchem continues to thrive in the global pharmaceutical market. The company maintains its focus on providing high-quality solutions and has gained recognition as a trusted partner in the industry. Asymchem's commitment to innovation, customer satisfaction, and global expansion positions it for continued growth and success in the future